Bradley Roberts

Mr. Bradley Roberts

The Perron Institute for Neurological and Translational Science, Perth, Western Australia, Australia
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
BRBradley Roberts
Bradley Roberts
ZCZahra Cooper
Zahra Cooper
SLStephanie Lu
Stephanie Lu
SSSusanne Stanley
Susanne Stanley
BMBernadette T. Majda
Bernadette T. Majda
SHSean D. Hood
Sean D. Hood
Pharmacogenetics (PGx) is the study and application of how interindividual differences in our genomes can influence drug responses. By evaluating individuals’ genetic variability in genes related to drug metabolism, PGx testing has the capabilities to individualise primary care and build a safer drug prescription model than the current “one-size-fits-all” approach. In particular, the use of PGx testing in psychiatry has shown promising evidence in improving drug efficacy as well as reducing toxicity and adverse drug reactions. Despite randomised controlled trials demonstrating an evidence base for its use, there are still numerous barriers impeding its implementation. This review paper will discuss the management of mental health conditions with PGx-guided treatment with a strong focus on youth mental illness. PGx testing in clinical practice, the concerns for its implementation in youth psychiatry, and some of the barriers inhibiting its integration in clinical healthcare will also be discussed. Overall, this paper provides a comprehensive review of the current state of knowledge and application for PGx in psychiatry and summarises the capabilities of genetic information to personalising medicine for the treatment of mental ill-health in youth.

Verified
Journal Article
Open access
PDF file
BRBradley Roberts
Bradley Roberts
FTFrances Theunissen
Frances Theunissen
FMFrank Mastaglia
Frank Mastaglia
PAP. Anthony Akkari
P. Anthony Akkari
LFLoren Flynn
Loren Flynn
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease classified as both a neurodegenerative and neuromuscular disorder. With a complex aetiology and no current cure for ALS, broadening the understanding of disease pathology and therapeutic avenues is required to progress with patient care. Alpha-synuclein (αSyn) is a hallmark for disease in neurodegenerative disorders, such as Parkinson’s disease, Lewy body dementia, and multiple system atrophy. A growing body of evidence now suggests that αSyn may also play a pathological role in ALS, with αSyn-positive Lewy bodies co-aggregating alongside known ALS pathogenic proteins, such as SOD1 and TDP-43. This review endeavours to capture the scope of literature regarding the aetiology and development of ALS and its commonalities with “synucleinopathy disorders”. We will discuss the involvement of αSyn in ALS and motor neuron disease pathology, and the current theories and strategies for therapeutics in ALS treatment, as well as those targeting αSyn for synucleinopathies, with a core focus on small molecule RNA technologies.

3 January 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BRBradley Roberts
Bradley Roberts
ZCZahra Cooper
Zahra Cooper
GLGeorgia Landery
Georgia Landery
SSSusanne Stanley
Susanne Stanley
BMBernadette T. Majda
Bernadette T. Majda
JRJennifer Rodger
Jennifer Rodger
Introduction: The field of pharmacogenetics (PGx) is experiencing significant growth, with increasing evidence to support its application in psychiatric care, suggesting its potential to personalize treatment plans, optimize medication efficacy, and reduce adverse drug reactions. However, the perceived utility and practicability of PGx for psychiatric treatment in youth remains underexplored. This study investigated perceived barriers and attitudes in Australian young adults towards the implementation of PGx testing to guide antidepressant treatment in primary care.Methods: Semi-structured focus groups and interviews were conducted with 17 participants aged between 18 and 24 years. These sessions were recorded and transcribed before thematic analysis was used to identify collective themes.Results: Three key themes were identified, including attitudes towards the medication prescription process, concerns and attitudes towards PGx testing, and perceived barriers to its clinical implementation. Although PGx testing was positively perceived by most participants, all participants shared concerns about PGx testing. Participants voiced concerns about the financial impact of PGx testing, the potential for treatment delays, and the accuracy of PGx testing in guiding antidepressant treatment. Additionally, participants noted that the low awareness and willingness of general practitioners to incorporate PGx testing into routine practice could hinder successful clinical implementation.Discussion: Prior to the implementation of PGx testing into Australian primary practices, it is essential to acknowledge patient perspectives and ensure that clinical practices remain patient-focused. This study highlights important considerations for integrating PGx testing into antidepressant pharmacotherapy and emphasizes the need for future research to address and mitigate the perceived barriers of young adults.

11 November 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
BRBradley Roberts
Bradley Roberts
ZCZahra Cooper
Zahra Cooper
AMAleksandra Miljevic
Aleksandra Miljevic
SSSusanne H Stanley
Susanne H Stanley
BMBernadette T Majda
Bernadette T Majda
JRJennifer Rodger
Jennifer Rodger
Background: The prevalence of depression and mood disorders has been steadily rising in Australian youth, with a concomitant increase in antidepressant pharmacotherapy prescription rates. Yet, the tolerability and efficacy of antidepressant drugs in youth remain poor. Pharmacogenetic (PGx) testing, or the personalised and guided treatment of medication based on genetic data, has been suggested to improve the effectiveness and tolerability of antidepressants. However, limited studies have evaluated the utility of antidepressant PGx-guided treatment in adolescent and young adult populations. Thus, this pilot randomised controlled trial (RCT), the GENE-YD Study, will evaluate the feasibility for a large-scale RCT assessing the effect of PGx-guided antidepressant prescription vs treatment as usual in youth with major depressive disorder (MDD). Methods and analysis: Eighty young people between 16 and 24 years of age and in the early stages of pharmacotherapy treatment for MDD will be recruited. Following initial screening, participants will be randomised on a 1:1 ratio to either the intervention or control study group. Participants in the intervention condition will have their treatment tailored based on their PGx profile. Participants randomised into the control group will have their prescription based on current best practice recommendations, or treatment as usual. Individuals will be assessed at drug prescription baseline and again 6 and 12 weeks following drug prescription. The primary outcome of the study will be to evaluate the feasibility and acceptability of the GENE-YD protocol. Specifically, this study will explore participation recruitment strategies and attrition to the study protocols to guide the recruitment processes of a large-scale RCT, along with participating satisfaction in overall study protocols. Secondary outcomes will inform the utility and variability of specific measures (eg, depression rating scales, quality of life measures and medication adherence scales) that may be scaled up for use in a future full-scale trial. Ethics and dissemination: Ethics approval was granted by the Department of Health, Western Australia’s Human Research Ethics Committee (RGS0000006822) and recognised by the University of Western Australia’s Human Research Ethics Committee (2024/ET000685). All participants will be required to provide written informed consent. Results will be published in international peer-reviewed journals. Trial registration number: ACTRN12624000760572.

1 April 2026 in Psychology of Men & Masculinities
Verified
Journal Article
Open access
VMVincent Mancini
Vincent Mancini
JBJack D. Brett
Jack D. Brett
MMMahdi Mazidi
Mahdi Mazidi
TNThomas P. Nevill
Thomas P. Nevill
BRBradley Roberts
Bradley Roberts
ZSZac Seidler
Zac Seidler

26 March 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BRBradley Roberts
Bradley Roberts
ZCZahra Cooper
Zahra Cooper
GLGeorgia Landery
Georgia Landery
SSSusanne Stanley
Susanne Stanley
BMBernadette T. Majda
Bernadette T. Majda
JRJennifer Rodger
Jennifer Rodger
Corrigendum: Exploring Perceived Barriers and Attitudes in Young Adults Towards Antidepressant Pharmacotherapy, Including the Implementation of Pharmacogenetic Testing to Optimize Prescription Practices* Correspondence: Bradley Roberts, brad.roberts@perron.uwa.edu.au; Zahra Cooper, zahra.cooper@perron.uwa.edu.auKeywords: same as original articleCorrigendum on: Roberts B, Cooper Z, Landery G, Stanley S, Majda BT, Collins KRL, Akkari PA, Hood SD and Rodger J (2025) Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices. Front. Pharmacol. 15:1526101. doi: 10.3389/fphar.2024.1526101 Text CorrectionIn the published article, there was an error. A general nation-wide statistic has been stated incorrectly during changes made in the review process. Whilst the grammatical/typo error is minor in nature, this correction is necessary to stop misinformation and improper citations.A correction has been made to 1. Introduction, Paragraph 2. This sentence previously stated:“The Australian prescription rate of antidepressants has risen by ∼25% per annum over the past 7 years (Australian Institute of Health and Welfare, 2023; Australian Institute of Health and Welfare, 2022; Australian Institute of Health and Welfare, 2021a; Australian Institute of Health and Welfare, 2020; Australian Institute of Health and Welfare, 2019; Australian Institute of Health and Welfare, 2018), with over 33 million antidepressants prescribed in 2023 alone (Australian Institute of Health and Welfare, 2023).”The corrected sentence appears below:“The Australian prescription rate of antidepressants has risen by ∼33% over the past 7 years (Australian Institute of Health and Welfare, 2023; Australian Institute of Health and Welfare, 2022; Australian Institute of Health and Welfare, 2021a; Australian Institute of Health and Welfare, 2020; Australian Institute of Health and Welfare, 2019; Australian Institute of Health and Welfare, 2018), with over 33 million antidepressants prescribed in 2023 alone (Australian Institute of Health and Welfare, 2023).”The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.